{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:42:53Z","timestamp":1778035373002,"version":"3.51.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer UK Limited"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The objective of this study was to review our clinical experience on the safety and efficacy of anidulafungin, an echinocandin antifungal, in the treatment of invasive fungal infections (IFIs) in patients with moderate to severe abnormal liver function tests or multiorgan failure and IFI, in a large United Kingdom Liver Centre.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The clinical records of the first 50 consecutive patients treated for IFI with anidulafungin between January 7, 2009 and March 2, 2011 were analyzed. Data were collected on demographics, underlying disease, disease characteristics, hematological and biochemical parameters, IFI, concomitant bacterial and viral infections, response to anidulafungin, and anidulafungin-related adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The patients\u2019 median age was 54.3 years (range, 19.6\u201375.9); 60% were male. Twenty-two (44%) patients were liver transplant recipients. Others had hepatopancreaticobiliary disease (n = 15, 30%) or chronic liver disease (n = 11, 22%). Invasive fungal infection (predominantly Candida spp) was proven in 36 (72%) patients, probable in 14 (28%). Of 46 evaluable patients, 35 (76%) had a favorable anidulafungin treatment outcome. Forty-nine (98%) had abnormal liver function tests (LFTs) pretreatment; 31 (62%) had \u22651 LFT raised to \u22652\u00d7 baseline during anidulafungin treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this highly specialized group of patients, anidulafungin treatment was efficacious and well tolerated by those with decompensated liver disease, multiorgan failure, and high-risk liver transplant with proven or probable IFI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofw241","type":"journal-article","created":{"date-parts":[[2016,11,13]],"date-time":"2016-11-13T01:39:05Z","timestamp":1479001145000},"source":"Crossref","is-referenced-by-count":12,"title":["Safety and Efficacy of Anidulafungin for Fungal Infection in Patients With Liver Dysfunction or Multiorgan Failure"],"prefix":"10.1093","volume":"4","author":[{"given":"Anita","family":"Verma","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Auzinger","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies, King\u2019s College Hospital, Denmark Hill, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Kantecki","sequence":"additional","affiliation":[{"name":"Pfizer PFE, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Campling","sequence":"additional","affiliation":[{"name":"Pfizer Limited, Tadworth, Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Spurden","sequence":"additional","affiliation":[{"name":"Pfizer Limited, Tadworth, Surrey, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran","family":"Percival","sequence":"additional","affiliation":[{"name":"pH Associates, Marlow, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Heaton","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies, King\u2019s College Hospital, Denmark Hill, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,11,12]]},"reference":[{"key":"2020081004563021900_CIT0001","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijantimicag.2006.01.002","article-title":"Candidaemia in Europe: epidemiology and resistance","volume":"27","author":"Tortorano","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"2020081004563021900_CIT0002","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004563021900_CIT0003","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2020081004563021900_CIT0004","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1469-0691.2012.03784.x","article-title":"Anidulafungin for the treatment of candidaemia\/invasive candidiasis in selected critically ill patients","volume":"18","author":"Ruhnke","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2020081004563021900_CIT0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.riam.2014.10.003","article-title":"Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment","volume":"32","author":"Montesinos","year":"2015","journal-title":"Rev Iberoam Micol"},{"key":"2020081004563021900_CIT0006","article-title":"Anidulafungin biotransformation in humans is by degradation not metabolism","volume-title":"Program and Abstracts of the 13th European Congress of Clinical Microbiology, and Infectious Diseases","author":"Stogniew","year":"2003"},{"key":"2020081004563021900_CIT0007","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0091270006297227","article-title":"Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment","volume":"47","author":"Dowell","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"2020081004563021900_CIT0008"},{"key":"2020081004563021900_CIT0009"},{"key":"2020081004563021900_CIT0010"},{"key":"2020081004563021900_CIT0011","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/2047-783X-16-4-159","article-title":"Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature","volume":"16","author":"Kofla","year":"2011","journal-title":"Eur J Med Res"},{"key":"2020081004563021900_CIT0012","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0091270004270146","article-title":"Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine","volume":"45","author":"Dowell","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"2020081004563021900_CIT0013","article-title":"Population pharmacokinetics confirms absence of anidulafungin drug-drug interactions","volume-title":"Program and Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases","author":"Stogniew","year":"2004"},{"key":"2020081004563021900_CIT0014","author":"King\u2019s College Hospital NHS Foundation Trust"},{"key":"2020081004563021900_CIT0015"},{"key":"2020081004563021900_CIT0016","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"2020081004563021900_CIT0017","author":"European Medicines Agency"},{"key":"2020081004563021900_CIT0018","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"2020081004563021900_CIT0019","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2003.50016","article-title":"Model for end-stage liver disease (MELD) and allocation of donor livers","volume":"124","author":"Wiesner","year":"2003","journal-title":"Gastroenterology"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/1\/ofw241\/33622087\/ofw241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/1\/ofw241\/33622087\/ofw241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:56:39Z","timestamp":1597049799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofw241\/2518866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofw241","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017]]},"published":{"date-parts":[[2016,11,12]]},"article-number":"ofw241"}}